Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com

Stock analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Down 8.3 %

Shares of EGRX stock opened at $0.55 on Monday. The company has a 50 day moving average price of $0.72 and a 200 day moving average price of $3.06. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $6.81.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Perceptive Advisors LLC acquired a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $971,000. Creative Planning acquired a new stake in Eagle Pharmaceuticals in the third quarter valued at approximately $59,000. Fidelis Capital Partners LLC purchased a new stake in shares of Eagle Pharmaceuticals during the second quarter valued at approximately $71,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Eagle Pharmaceuticals during the second quarter worth $76,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eagle Pharmaceuticals in the second quarter valued at $65,000. 85.36% of the stock is owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.